279 related articles for article (PubMed ID: 21460829)
1. Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia.
Xiong W; Cheng K; Cui T; Godlewski G; Rice KC; Xu Y; Zhang L
Nat Chem Biol; 2011 May; 7(5):296-303. PubMed ID: 21460829
[TBL] [Abstract][Full Text] [Related]
2. A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors.
Xiong W; Wu X; Li F; Cheng K; Rice KC; Lovinger DM; Zhang L
J Neurosci; 2012 Apr; 32(15):5200-8. PubMed ID: 22496565
[TBL] [Abstract][Full Text] [Related]
3. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for cannabinoid-induced potentiation of alpha1-glycine receptors in lipid nanodiscs.
Kumar A; Kindig K; Rao S; Zaki AM; Basak S; Sansom MSP; Biggin PC; Chakrapani S
Nat Commun; 2022 Aug; 13(1):4862. PubMed ID: 35982060
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the role of CB
Li X; Hempel BJ; Yang HJ; Han X; Bi GH; Gardner EL; Xi ZX
Eur Neuropsychopharmacol; 2021 Feb; 43():38-51. PubMed ID: 33334652
[TBL] [Abstract][Full Text] [Related]
6. Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors.
Hejazi N; Zhou C; Oz M; Sun H; Ye JH; Zhang L
Mol Pharmacol; 2006 Mar; 69(3):991-7. PubMed ID: 16332990
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.
Xiong W; Cui T; Cheng K; Yang F; Chen SR; Willenbring D; Guan Y; Pan HL; Ren K; Xu Y; Zhang L
J Exp Med; 2012 Jun; 209(6):1121-34. PubMed ID: 22585736
[TBL] [Abstract][Full Text] [Related]
8. Involvement of glycine receptor α1 subunits in cannabinoid-induced analgesia.
Lu J; Fan S; Zou G; Hou Y; Pan T; Guo W; Yao L; Du F; Homanics GE; Liu D; Zhang L; Xiong W
Neuropharmacology; 2018 May; 133():224-232. PubMed ID: 29407767
[TBL] [Abstract][Full Text] [Related]
9. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
[TBL] [Abstract][Full Text] [Related]
10. Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine.
Yang Z; Aubrey KR; Alroy I; Harvey RJ; Vandenberg RJ; Lynch JW
Biochem Pharmacol; 2008 Oct; 76(8):1014-23. PubMed ID: 18755158
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoids Rescue Cocaine-Induced Seizures by Restoring Brain Glycine Receptor Dysfunction.
Zou G; Zuo X; Chen K; Ge Y; Wang X; Xu G; Wang H; Miao C; Xu Z; Tian S; Wang Z; Zhou Y; Wei W; Huang G; Liu D; Xiong W
Cell Rep; 2020 Mar; 30(12):4209-4219.e7. PubMed ID: 32209479
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.
DeLong GT; Wolf CE; Poklis A; Lichtman AH
Drug Alcohol Depend; 2010 Nov; 112(1-2):126-33. PubMed ID: 20619971
[TBL] [Abstract][Full Text] [Related]
13. Isolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal
Linciano P; Citti C; Luongo L; Belardo C; Maione S; Vandelli MA; Forni F; Gigli G; Laganà A; Montone CM; Cannazza G
J Nat Prod; 2020 Jan; 83(1):88-98. PubMed ID: 31891265
[TBL] [Abstract][Full Text] [Related]
14. Similarities and differences upon binding of naturally occurring Δ
Raïch I; Rivas-Santisteban R; Lillo A; Lillo J; Reyes-Resina I; Nadal X; Ferreiro-Vera C; de Medina VS; Majellaro M; Sotelo E; Navarro G; Franco R
Pharmacol Res; 2021 Dec; 174():105970. PubMed ID: 34758399
[TBL] [Abstract][Full Text] [Related]
15. [The synthetic cannabinoid analog WIN 55,212-2 potentiates the amplitudes of glycine-activated currents].
Iatsenko NM; Tsintsadze TSh; Lozova NO
Fiziol Zh (1994); 2007; 53(3):31-7. PubMed ID: 17725041
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
18. Receptor mechanisms underlying the CNS effects of cannabinoids: CB
Hempel B; Xi ZX
Adv Pharmacol; 2022; 93():275-333. PubMed ID: 35341569
[TBL] [Abstract][Full Text] [Related]
19. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.
Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF
J Pharmacol Exp Ther; 2018 May; 365(2):437-446. PubMed ID: 29549157
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
Booker L; Naidu PS; Razdan RK; Mahadevan A; Lichtman AH
Drug Alcohol Depend; 2009 Nov; 105(1-2):42-7. PubMed ID: 19679411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
